Myricitrin degraded by simulated digestion inhibits oxidation of human low-density lipoprotein.
The inhibitory effects of myricitrin on the oxidation of human low-density lipoprotein were investigated before and after its degradation by simulated digestion. Myricitrin strongly inhibited the low-density lipoprotein oxidation induced by either 2,2'-azobis (2-amidinopropane) dihydrochloride or CuSO4 in a concentration-dependent manner. Myricitrin was very stable under an acidic condition (pH 1.8) corresponding to the gastric environment, but it was easily degraded under an alkaline condition (pH 8.5) corresponding to the intestinal environment. However, degraded myricitrin also had a strong inhibitory effect on the oxidative degradation of alpha-tocopherol, cholesterol and apolipoprotein B-100 in low-density lipoprotein. Our study revealed that myricitrin was degraded into many components under a mildly alkaline condition, but the degraded myricitrin still retained the free radical-scavenging and copper-chelating activities toward low-density lipoprotein.
Yokomizo
Atsushi
A
Fundamental Research Division, San-Ei Gen F.F.I. Corporation, Osaka 561-8588, Japan.
Moriwaki
Masamitsu
M
D000578:Amidines / Q000494:pharmacology; D000975:Antioxidants / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000378:metabolism; D002614:Chelating Agents / Q000378:metabolism / Q000494:pharmacology; D002784:Cholesterol / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D003300:Copper / Q000378:metabolism / Q000494:pharmacology; D004063:Digestion; D004492:Edetic Acid / Q000378:metabolism / Q000494:pharmacology; D005419:Flavonoids / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D041981:Gastrointestinal Tract / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008077:Lipoproteins, LDL / Q000737:chemistry / Q000378:metabolism*; D015394:Molecular Structure; D010084:Oxidation-Reduction / Q000187:drug effects; D010627:Phenethylamines / Q000378:metabolism / Q000494:pharmacology; D013057:Spectrum Analysis; D024502:alpha-Tocopherol / Q000494:pharmacology
D000578:Amidines; D000975:Antioxidants; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D002614:Chelating Agents; D005419:Flavonoids; D008077:Lipoproteins, LDL; D010627:Phenethylamines; C057485:1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane; C008577:myricitrin; C046728:2,2'-azobis(2-amidinopropane); D003300:Copper; D002784:Cholesterol; D004492:Edetic Acid; D024502:alpha-Tocopherol